Skip to main content
. Author manuscript; available in PMC: 2015 Jun 1.
Published in final edited form as: Int J Stroke. 2014 Mar 24;9(4):443–448. doi: 10.1111/ijs.12267

Table 4. Independent participant characteristics associated with trial status.

All Sites Off assigned AP per patient request* Withdrew consent or lost to-follow-up*
Site location
 US/Canada ref group ref group
 Latin America 0.20 (0.10, 0.41) 0.32 (0.20, 0.51)
 Spain 0.54 (0.27, 1.1) 0.69 (0.43, 1.1)
# of prescription medications
 0-2 ref group ref group
 3-6 0.52 (0.32, 0.86) 1.2 (0.80, 1.7)
 7+ 0.63 (0.32, 1.3) 1.7 (1.1, 2.7)
Stroke-specific Quality of Life score at 3 months per 10 point decrease 1.2 (0.93, 1.5) 1.3 (1.1, 1.5)
US-Canada only Off assigned AP per patient request* Withdrew consent or lost to-follow-up*
# of prescription medications
 0-2 ref group ref group
 3-6 0.50 (0.29, 0.88) 1.3 (0.75, 2.2)
 7+ 0.41 (0.17, 0.94) 2.1 (1.1, 3.8)
Stroke-specific Quality of Life score at 3 months per 10 point decrease 1.2 (0.91, 1.5) 1.3 (1.1, 1.6)
*

compared to patients who continued on assigned antiplatelet (see methods)